Compare RCMT & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | HELP |
|---|---|---|
| Founded | 1971 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.2M | 233.0M |
| IPO Year | 1997 | N/A |
| Metric | RCMT | HELP |
|---|---|---|
| Price | $28.85 | $6.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $36.00 | ★ $51.50 |
| AVG Volume (30 Days) | 69.1K | ★ 1.3M |
| Earning Date | 04-03-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.38 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $12.46 | N/A |
| P/E Ratio | $54.81 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $3.76 |
| 52 Week High | $32.50 | $8.55 |
| Indicator | RCMT | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 65.71 | 66.28 |
| Support Level | $17.77 | $5.76 |
| Resistance Level | $32.39 | $6.26 |
| Average True Range (ATR) | 1.21 | 0.44 |
| MACD | 0.32 | 0.22 |
| Stochastic Oscillator | 81.64 | 73.11 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.